Covid, a final analysis of the Phase 3 study of the vaccine against the coronavirus of Pfizer shows that «is 95% effective» in preventing infections, even in the elderly, and has not caused serious safety problems, the company that makes the vaccine said.
Pfizer says a final trial analysis shows its Covid-19 vaccine is 95% effective with no safety concerns, and it will seek FDA emergency use “within days” https://t.co/fz9KwwcqcT
<!– #correlati article figure .player_clicker::after { color: #fff; background-color: rgba(0,0,0,0.6); border-radius: 50%; display: block; text-align: center; font-size: 16px; line-height: 40px; width: 40px; position: absolute; top: 50%; left: 50%; margin: -20px 0 0 -21px; } #correlati article figure .player_foto_clicker::after { color: #fff; background-color: rgba(0,0,0,0.6); border-radius: 50%; display: block; text-align: center; font-size: 20px; line-height: 40px; width: 40px; position: absolute; top: 50%; left: 50%; margin: -20px 0 0 -21px; }–>
— CNN Breaking News (@cnnbrk) November 18, 2020
The company counted 170 cases of coronavirus among the volunteers who took part in the trial. Pfizer said 162 infections were in people who received placebo, or simple saline injections, while 8 cases were in participants who received the actual vaccine. This works with 95 percent effectiveness, Pfizer said. «Efficacy was consistent across age, race, and demographic ethnicity.
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.
— Pfizer Inc. (@pfizer) November 18, 2020
The company plans to seek authorization for the vaccine within days, with a goal of going on distribution later this year if health regulators allow it. «The results of the study mark an important step in this historic 8-month journey for a vaccine that can help put an end to this devastating one pandemicPfizer CEO Albert Bourla said in a statement. If the FDA clears the two-dose vaccine, Pfizer said it could have up to 50 million doses available by the end of the year, and up to 1.3 billion by the end of next year.
—
Efficacy observed in adults over 65 years of age was greater than 94%»Pfizer and its German partner BioNTech said in a joint statement. The vaccine has been tested at 43,500 people in six countries and there do not appear to be any safety concerns at the moment.
Last updated: 13:45
© REPRODUCTION RESERVED – below) // the var will be used by PaywallMeter to target the event on the correct pixel settings_testata.fbq_swg_promo = ‘556738118336305’; fbq (‘init’, header_settings.fbq_swg_promo); fbq (‘track’, ‘PageView’);
.
